Please wait while the formulary information is being retrieved.
VISTARIL (HYDROXYZINE PAMOATE)
- Anxiety
- Sedation as adjunct to anesthesia
- Allergic dermatitis
- Pruritus of skin
- Urticaria
25 mg capsule
- 1 capsule (25 mg) by oral route 4 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 4 times per day
100 mg capsule
- 1 capsule (100 mg) by oral route 4 times per day
25 mg capsule
- 1 capsule (25 mg) by oral route 4 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 4 times per day
Anxiety
- 2 capsules (50 mg) by oral route 4 times per day
- 1 capsule (50 mg) by oral route 4 times per day
- 2 capsules (100 mg) by oral route 4 times per day
Pruritus of skin
- 1 capsule (25 mg) by oral route 3 times per day
- 1 capsule (25 mg) by oral route 4 times per day
Urticaria
- 1 capsule (25 mg) by oral route 3 times per day
- 1 capsule (25 mg) by oral route 4 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- Angle-closure glaucoma
Contraindicated
- Acute myocardial infarction
- Bladder outflow obstruction
- Chronic heart failure
- Congenital long QT syndrome
- Hypokalemia
- Hypomagnesemia
- Pregnancy
- Prolonged QT interval
- Pyloroduodenal obstruction
- Stenosing peptic ulcer
- Urinary retention
Severe
Moderate
- Benign prostatic hyperplasia
- Constipation
- Open angle glaucoma
VISTARIL (HYDROXYZINE PAMOATE)
- Anxiety
- Sedation as adjunct to anesthesia
- Allergic dermatitis
- Pruritus of skin
- Urticaria
- None
- Drowsy
- Xerostomia
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute generalized exanthematous pustulosis
- Hallucinations
- Prolonged QT interval
- Seizure disorder
- Torsades de pointes
Less Severe
- Headache disorder
- Pruritus of skin
- Skin rash
- Tremor
- Urticaria
Contraindicated
None
Severe Precaution
Hydroxyzine
Risk of adverse CNS effects, drowsiness or tremor/convulsions. Lack of safety data,
- 1 Day – 179 Days
- Risk of adverse CNS effects, drowsiness or tremor/convulsions. Lack of safety data,
Management or Monitoring Precaution
None
Hydroxyzine
- Severity Level:
D
- Additional Notes: Insuff human data; 2 reports of neonatal withdrawal and seizures.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Hydroxyzine
Use not recommended; low molecular weight suggests possible excretion in milk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Use not recommended; low molecular weight suggests possible excretion in milk |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Hydroxyzine
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Maximum recommended geriatric dose 50mg/day for as short a duration as possible. Gastrointestinal-May cause or worsen pre-existing constipation. Urogenital-Best avoided in patients with urinary retention from any cause. Cardiovascular-Risk for Torsades de pointes. Follow QTc intervals.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Allergic dermatitis | |
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.83 | Infantile (acute) (chronic) eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| L23 | Allergic contact dermatitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L23.8 | Allergic contact dermatitis due to other agents |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
| L23.89 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| Anxiety | |
| F06.4 | Anxiety disorder due to known physiological condition |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder |
| F12.980 | Cannabis use, unspecified with anxiety disorder |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder |
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder |
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder |
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder |
| F40 | Phobic anxiety disorders |
| F40.0 | Agoraphobia |
| F40.00 | Agoraphobia, unspecified |
| F40.01 | Agoraphobia with panic disorder |
| F40.02 | Agoraphobia without panic disorder |
| F40.1 | Social phobias |
| F40.10 | Social phobia, unspecified |
| F40.11 | Social phobia, generalized |
| F40.8 | Other phobic anxiety disorders |
| F40.9 | Phobic anxiety disorder, unspecified |
| F41 | Other anxiety disorders |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] |
| F41.1 | Generalized anxiety disorder |
| F41.3 | Other mixed anxiety disorders |
| F41.8 | Other specified anxiety disorders |
| F41.9 | Anxiety disorder, unspecified |
| F93.0 | Separation anxiety disorder of childhood |
| Pruritus of skin | |
| L29.8 | Other pruritus |
| L29.9 | Pruritus, unspecified |
| Urticaria | |
| L50 | Urticaria |
| L50.0 | Allergic urticaria |
| L50.1 | Idiopathic urticaria |
| L50.2 | Urticaria due to cold and heat |
| L50.3 | Dermatographic urticaria |
| L50.4 | Vibratory urticaria |
| L50.5 | Cholinergic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |
| L50.9 | Urticaria, unspecified |
| L56.3 | Solar urticaria |
| O26.86 | Pruritic urticarial papules and plaques of pregnancy (PUPPp) |
| 0-9 | A-Z |
|---|---|
| F06.4 | Anxiety disorder due to known physiological condition |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder |
| F12.980 | Cannabis use, unspecified with anxiety disorder |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder |
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder |
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder |
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder |
| F40 | Phobic anxiety disorders |
| F40.0 | Agoraphobia |
| F40.00 | Agoraphobia, unspecified |
| F40.01 | Agoraphobia with panic disorder |
| F40.02 | Agoraphobia without panic disorder |
| F40.1 | Social phobias |
| F40.10 | Social phobia, unspecified |
| F40.11 | Social phobia, generalized |
| F40.8 | Other phobic anxiety disorders |
| F40.9 | Phobic anxiety disorder, unspecified |
| F41 | Other anxiety disorders |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] |
| F41.1 | Generalized anxiety disorder |
| F41.3 | Other mixed anxiety disorders |
| F41.8 | Other specified anxiety disorders |
| F41.9 | Anxiety disorder, unspecified |
| F93.0 | Separation anxiety disorder of childhood |
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.83 | Infantile (acute) (chronic) eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| L23 | Allergic contact dermatitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L23.8 | Allergic contact dermatitis due to other agents |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
| L23.89 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| L29.8 | Other pruritus |
| L29.9 | Pruritus, unspecified |
| L50 | Urticaria |
| L50.0 | Allergic urticaria |
| L50.1 | Idiopathic urticaria |
| L50.2 | Urticaria due to cold and heat |
| L50.3 | Dermatographic urticaria |
| L50.4 | Vibratory urticaria |
| L50.5 | Cholinergic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |
| L50.9 | Urticaria, unspecified |
| L56.3 | Solar urticaria |
| O26.86 | Pruritic urticarial papules and plaques of pregnancy (PUPPp) |
Formulary Reference Tool